3 Red Flags for Moderna's Potential Coronavirus Vaccine

3 Red Flags for Moderna's Potential Coronavirus Vaccine

Moderna's (NASDAQ: MRNA) coronavirus vaccine efforts have made the biotech into a household name, fueling its impressive stock-price growth in the process. As shown by positive data from the first two phases of its clinical trials, Moderna's mRNA-1273 vaccine has a solid chance of winning the global race for a coronavirus prophylactic. The company's insiders have made high-profile exits from their stock positions.